APO Research
Talk to an analyst

APO RESEARCH · REPORT

Juvenile Idiopathic Arthritis Diagnostic

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Juvenile Idiopathic Arthritis Diagnostic Market Outlook and Growth Opportunities 2026

27 December 2025197 pages

Choose your research edition.

Industry ResearchJuvenile Idiopathic Arthritis Diagnostic Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Juvenile Idiopathic Arthritis Diagnostic Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Juvenile Idiopathic Arthritis Diagnostic Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Juvenile Idiopathic Arthritis Diagnostic Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Juvenile Idiopathic Arthritis Diagnostic Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Juvenile Idiopathic Arthritis Diagnostic market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Juvenile Idiopathic Arthritis Diagnostic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Juvenile Idiopathic Arthritis Diagnostic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Juvenile Idiopathic Arthritis Diagnostic is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Juvenile Idiopathic Arthritis Diagnostic market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Juvenile Idiopathic Arthritis Diagnostic market include Abbott, Roche, United Imaging, Philips, Thermo Fisher Scientific, Sysmex, Siemens Healthineers, Siemens and Hitachi, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Juvenile Idiopathic Arthritis Diagnostic market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Juvenile Idiopathic Arthritis Diagnostic and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Juvenile Idiopathic Arthritis Diagnostic revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Juvenile Idiopathic Arthritis Diagnostic market.

Juvenile Idiopathic Arthritis Diagnostic Segment by Company

Abbott

Roche

United Imaging

Philips

Thermo Fisher Scientific

Sysmex

Siemens Healthineers

Siemens

Hitachi

GE

Danaher

Canon Medical

BioMerieux

Juvenile Idiopathic Arthritis Diagnostic Segment by Type

Blood Tests

Imaging Scans

Juvenile Idiopathic Arthritis Diagnostic Segment by Application

Hospitals

Laboratories

Other

Juvenile Idiopathic Arthritis Diagnostic Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Juvenile Idiopathic Arthritis Diagnostic status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Juvenile Idiopathic Arthritis Diagnostic key companies, revenue, market share, and recent developments.

3. To split the Juvenile Idiopathic Arthritis Diagnostic breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Juvenile Idiopathic Arthritis Diagnostic market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Juvenile Idiopathic Arthritis Diagnostic significant trends, drivers, influence factors in global and regions.

6. To analyze Juvenile Idiopathic Arthritis Diagnostic competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Juvenile Idiopathic Arthritis Diagnostic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Juvenile Idiopathic Arthritis Diagnostic and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Juvenile Idiopathic Arthritis Diagnostic.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Juvenile Idiopathic Arthritis Diagnostic industry.

Chapter 3: Detailed analysis of Juvenile Idiopathic Arthritis Diagnostic company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Juvenile Idiopathic Arthritis Diagnostic in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Juvenile Idiopathic Arthritis Diagnostic in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Juvenile Idiopathic Arthritis Diagnostic Industry Trends Table 2. Juvenile Idiopathic Arthritis Diagnostic Industry Drivers Table 3. Juvenile Idiopathic Arthritis Diagnostic Industry Opportunities and Challenges Table 4. Juvenile Idiopathic Arthritis Diagnostic Industry Restraints Table 5. Global Juvenile Idiopathic Arthritis Diagnostic Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Juvenile Idiopathic Arthritis Diagnostic Revenue Share by Company (2021-2026) Table 7. Global Juvenile Idiopathic Arthritis Diagnostic Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Juvenile Idiopathic Arthritis Diagnostic Key Company Manufacturing Base & Headquarters Table 9. Global Juvenile Idiopathic Arthritis Diagnostic Company, Product Type & Application Table 10. Global Juvenile Idiopathic Arthritis Diagnostic Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Juvenile Idiopathic Arthritis Diagnostic by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Blood Tests Table 15. Significant Companies of Imaging Scans Table 16. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type (2021-2026) Table 20. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospitals Table 22. Significant Companies of Laboratories Table 23. Significant Companies of Other Table 24. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application (2021-2026) Table 28. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application (2027-2032) Table 29. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Region (2021-2026) Table 32. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Region (2027-2032) Table 34. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Market Share by Country (2021-2026) Table 37. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Market Share by Country (2027-2032) Table 39. Abbott Company Information Table 40. Abbott Business Overview Table 41. Abbott Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Abbott Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 43. Abbott Recent Development Table 44. Roche Company Information Table 45. Roche Business Overview Table 46. Roche Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Roche Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 48. Roche Recent Development Table 49. United Imaging Company Information Table 50. United Imaging Business Overview Table 51. United Imaging Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. United Imaging Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 53. United Imaging Recent Development Table 54. Philips Company Information Table 55. Philips Business Overview Table 56. Philips Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Philips Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 58. Philips Recent Development Table 59. Thermo Fisher Scientific Company Information Table 60. Thermo Fisher Scientific Business Overview Table 61. Thermo Fisher Scientific Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Thermo Fisher Scientific Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 63. Thermo Fisher Scientific Recent Development Table 64. Sysmex Company Information Table 65. Sysmex Business Overview Table 66. Sysmex Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Sysmex Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 68. Sysmex Recent Development Table 69. Siemens Healthineers Company Information Table 70. Siemens Healthineers Business Overview Table 71. Siemens Healthineers Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Siemens Healthineers Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 73. Siemens Healthineers Recent Development Table 74. Siemens Company Information Table 75. Siemens Business Overview Table 76. Siemens Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Siemens Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 78. Siemens Recent Development Table 79. Hitachi Company Information Table 80. Hitachi Business Overview Table 81. Hitachi Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Hitachi Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 83. Hitachi Recent Development Table 84. GE Company Information Table 85. GE Business Overview Table 86. GE Juvenile Idiopathic Arthritis Diagnostic Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. GE Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 88. GE Recent Development Table 89. Danaher Company Information Table 90. Danaher Business Overview Table 91. Danaher Juvenile Idiopathic Arthritis Diagnostic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Danaher Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 93. Danaher Recent Development Table 94. Canon Medical Company Information Table 95. Canon Medical Business Overview Table 96. Canon Medical Juvenile Idiopathic Arthritis Diagnostic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Canon Medical Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 98. Canon Medical Recent Development Table 99. BioMerieux Company Information Table 100. BioMerieux Business Overview Table 101. BioMerieux Juvenile Idiopathic Arthritis Diagnostic Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. BioMerieux Juvenile Idiopathic Arthritis Diagnostic Product Portfolio Table 103. BioMerieux Recent Development Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Juvenile Idiopathic Arthritis Diagnostic Product Image Figure 2. Global Juvenile Idiopathic Arthritis Diagnostic Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Juvenile Idiopathic Arthritis Diagnostic Market Size (2021-2032) & (US$ Million) Figure 4. Global Juvenile Idiopathic Arthritis Diagnostic Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Blood Tests Image Figure 8. Imaging Scans Image Figure 9. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type (2021-2032) Figure 12. Hospitals Image Figure 13. Laboratories Image Figure 14. Other Image Figure 15. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application (2021-2032) Figure 18. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032) & (US$ Million) Figure 21. North America Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032) & (US$ Million) Figure 27. South America Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Blood Tests
  • Imaging Scans
Applications
  • Hospitals
  • Laboratories
  • Other
Companies covered
  • Abbott
  • Roche
  • United Imaging
  • Philips
  • Thermo Fisher Scientific
  • Sysmex
  • Siemens Healthineers
  • Siemens
  • Hitachi
  • GE
  • Danaher
  • Canon Medical
  • BioMerieux

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Juvenile Idiopathic Arthritis Diagnostic Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Juvenile Idiopathic Arthritis Diagnostic Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Juvenile Idiopathic Arthritis Diagnostic Market Dynamics
  1. 2.1 Juvenile Idiopathic Arthritis Diagnostic Industry Trends
  2. 2.2 Juvenile Idiopathic Arthritis Diagnostic Industry Drivers
  3. 2.3 Juvenile Idiopathic Arthritis Diagnostic Industry Opportunities and Challenges
  4. 2.4 Juvenile Idiopathic Arthritis Diagnostic Industry Restraints
3 Juvenile Idiopathic Arthritis Diagnostic Market by Company
  1. 3.1 Global Juvenile Idiopathic Arthritis Diagnostic Company Revenue Ranking in 2025
  2. 3.2 Global Juvenile Idiopathic Arthritis Diagnostic Revenue by Company (2021-2026)
  3. 3.3 Global Juvenile Idiopathic Arthritis Diagnostic Company Ranking (2024-2026)
  4. 3.4 Global Juvenile Idiopathic Arthritis Diagnostic Company Manufacturing Base and Headquarters
  5. 3.5 Global Juvenile Idiopathic Arthritis Diagnostic Company Product Type and Application
  6. 3.6 Global Juvenile Idiopathic Arthritis Diagnostic Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Juvenile Idiopathic Arthritis Diagnostic Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Juvenile Idiopathic Arthritis Diagnostic Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Juvenile Idiopathic Arthritis Diagnostic Market by Type
  1. 4.1 Juvenile Idiopathic Arthritis Diagnostic Type Introduction
  2. 4.1.1 Blood Tests
  3. 4.1.2 Imaging Scans
  4. 4.2 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Type
  5. 4.2.1 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Type (2021-2032)
  7. 4.2.3 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type (2021-2032)
5 Juvenile Idiopathic Arthritis Diagnostic Market by Application
  1. 5.1 Juvenile Idiopathic Arthritis Diagnostic Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Laboratories
  4. 5.1.3 Other
  5. 5.2 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Application
  6. 5.2.1 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Application (2021-2032)
  8. 5.2.3 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application (2021-2032)
6 Juvenile Idiopathic Arthritis Diagnostic Regional Value Analysis
  1. 6.1 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Region (2021-2032)
  3. 6.2.1 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Region: 2021-2026
  4. 6.2.2 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032)
  7. 6.3.2 North America Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032)
  10. 6.4.2 Europe Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032)
  16. 6.6.2 South America Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Juvenile Idiopathic Arthritis Diagnostic Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Country, 2025 VS 2032
7 Juvenile Idiopathic Arthritis Diagnostic Country-level Value Analysis
  1. 7.1 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Country (2021-2032)
  3. 7.2.1 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Country (2021-2026)
  4. 7.2.2 Global Juvenile Idiopathic Arthritis Diagnostic Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Juvenile Idiopathic Arthritis Diagnostic Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Juvenile Idiopathic Arthritis Diagnostic Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 United Imaging
  14. 8.3.1 United Imaging Company Information
  15. 8.3.2 United Imaging Business Overview
  16. 8.3.3 United Imaging Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  17. 8.3.4 United Imaging Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  18. 8.3.5 United Imaging Recent Developments
  19. 8.4 Philips
  20. 8.4.1 Philips Company Information
  21. 8.4.2 Philips Business Overview
  22. 8.4.3 Philips Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Philips Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  24. 8.4.5 Philips Recent Developments
  25. 8.5 Thermo Fisher Scientific
  26. 8.5.1 Thermo Fisher Scientific Company Information
  27. 8.5.2 Thermo Fisher Scientific Business Overview
  28. 8.5.3 Thermo Fisher Scientific Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Thermo Fisher Scientific Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  30. 8.5.5 Thermo Fisher Scientific Recent Developments
  31. 8.6 Sysmex
  32. 8.6.1 Sysmex Company Information
  33. 8.6.2 Sysmex Business Overview
  34. 8.6.3 Sysmex Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sysmex Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  36. 8.6.5 Sysmex Recent Developments
  37. 8.7 Siemens Healthineers
  38. 8.7.1 Siemens Healthineers Company Information
  39. 8.7.2 Siemens Healthineers Business Overview
  40. 8.7.3 Siemens Healthineers Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Siemens Healthineers Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  42. 8.7.5 Siemens Healthineers Recent Developments
  43. 8.8 Siemens
  44. 8.8.1 Siemens Company Information
  45. 8.8.2 Siemens Business Overview
  46. 8.8.3 Siemens Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Siemens Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  48. 8.8.5 Siemens Recent Developments
  49. 8.9 Hitachi
  50. 8.9.1 Hitachi Company Information
  51. 8.9.2 Hitachi Business Overview
  52. 8.9.3 Hitachi Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hitachi Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  54. 8.9.5 Hitachi Recent Developments
  55. 8.10 GE
  56. 8.10.1 GE Company Information
  57. 8.10.2 GE Business Overview
  58. 8.10.3 GE Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  59. 8.10.4 GE Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  60. 8.10.5 GE Recent Developments
  61. 8.11 Danaher
  62. 8.11.1 Danaher Company Information
  63. 8.11.2 Danaher Business Overview
  64. 8.11.3 Danaher Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Danaher Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  66. 8.11.5 Danaher Recent Developments
  67. 8.12 Canon Medical
  68. 8.12.1 Canon Medical Company Information
  69. 8.12.2 Canon Medical Business Overview
  70. 8.12.3 Canon Medical Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Canon Medical Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  72. 8.12.5 Canon Medical Recent Developments
  73. 8.13 BioMerieux
  74. 8.13.1 BioMerieux Company Information
  75. 8.13.2 BioMerieux Business Overview
  76. 8.13.3 BioMerieux Juvenile Idiopathic Arthritis Diagnostic Revenue and Gross Margin (2021-2026)
  77. 8.13.4 BioMerieux Juvenile Idiopathic Arthritis Diagnostic Product Portfolio
  78. 8.13.5 BioMerieux Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst